Go Premium in Our Biggest Sale Ever

Go Ultimate 75% OFF

DE:L9S Stock Latest News

RatingsGyre’s Solid ETUARY Sales and F351 Opportunity Support Bullish Outlook; $18 Price Target Unchanged6d agoGYRE

Company AnnouncementsGyre Therapeutics Secures CEO and CFO with New Contracts3w ago8K GYRE
Company AnnouncementsGyre Therapeutics Highlights Capital-Efficient Global Development Strategy2M ago8K GYRE
Company AnnouncementsGyre Therapeutics unveils capital-efficient global development strategy2M ago8K GYRE
Company AnnouncementsThin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks3M agoGYRE

Gyre Therapeutics Strengthens Board with New Director Appointments

Company AnnouncementsGyre Therapeutics Strengthens Board with New Director Appointments3M ago8K GYRE

The FlyGyre Therapeutics files to sell 30.22M shares of common stock for holders4M agoGYRE

Company AnnouncementsGyre Therapeutics Shareholders Approve Directors and Governance Measures4M ago8K GYRE

Company AnnouncementsGyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy5M ago8K GYRE
Company AnnouncementsGyre Therapeutics Highlights Cullgen Acquisition and Pipeline Expansion6M ago8K GYRE
Company AnnouncementsGyre Therapeutics’ F351 NDA Accepted for Priority Review6M ago8K GYRE
The FlyGyre Therapeutics announces China NMPA acceptance of F351 NDA6M agoGYRE

Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year

The FlyGyre Therapeutics reports Q1 EPS (10c) vs. 0c last year6M agoGYRE

Pre-EarningsGYRE Upcoming Earnings Report: What to Expect?6M agoGYRE

Company AnnouncementsGyre Therapeutics Completes Cullgen Acquisition and Leadership Transition6M ago8K GYRE

Company AnnouncementsGyre Therapeutics Files NDA in China for F3517M ago8K GYRE
RatingsBuy Rating on Gyre Therapeutics Driven by Priority Review of Hydronidone in China and De-Risked Path to 2026 Conditional Approval8M agoGYRE
The FlyGyre Therapeutics’ liver fibrosis candidate granted priority review in China8M agoGYRE
Company AnnouncementsGyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions8M agoGYRE

Gyre Therapeutics Projects Strong Growth for Fibrosis Programs

Company AnnouncementsGyre Therapeutics Projects Strong Growth for Fibrosis Programs8M ago8K GYRE

The FlyGyre Therapeutics reports Q4 EPS (2c), consensus 1c8M agoGYRE

The FlyGyre Therapeutics sees FY26 revenue $100.5M-$111M, consensus $148M8M agoGYRE